Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

552

Participants

Timeline

Start Date

October 31, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

February 8, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 300SU/0.5ml

BIOLOGICAL

Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml

OTHER

Two doses of placebo at the schedule of day 0,28

The placebo contains no active ingredient and manufactured by Sinovac Research \& Development Co., Ltd.

Trial Locations (1)

051230

Zanhuang county Center for Disease Control and Prevention, Shijiazhuang

All Listed Sponsors
lead

Sinovac Research and Development Co., Ltd.

INDUSTRY

NCT04551547 - Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19 | Biotech Hunter | Biotech Hunter